We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Agilent (A) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Agilent Technologies (A - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.27 per share, reflecting an increase of 4.1% compared to the same period last year. Revenues are forecasted to be $1.63 billion, representing a year-over-year increase of 3.3%.
The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Agilent metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenue by End Markets- Diagnostics and Clinical' at $247.93 million. The estimate suggests a change of +3.7% year over year.
Analysts predict that the 'Revenue by End Markets- Chemical and advanced materials' will reach $370.20 million. The estimate points to a change of +2.3% from the year-ago quarter.
The consensus among analysts is that 'Revenue by End Markets- Food' will reach $146.05 million. The estimate indicates a year-over-year change of +5.1%.
Analysts expect 'Revenue by End Markets- Academia and Government' to come in at $145.13 million. The estimate suggests a change of +4.4% year over year.
Analysts' assessment points toward 'Net Revenue- Life Sciences and Applied Markets Group' reaching $628.72 million. The estimate suggests a change of -16.6% year over year.
The consensus estimate for 'Net Revenue- Agilent Crosslab Group' stands at $697.53 million. The estimate indicates a year-over-year change of +73.5%.
Analysts forecast 'Revenue by End Markets- Pharmaceutical' to reach $572.63 million. The estimate indicates a change of +5.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue by End Markets- Environmental and Forensics' should come in at $159.54 million. The estimate points to a change of +5% from the year-ago quarter.
Over the past month, shares of Agilent have returned +3.7% versus the Zacks S&P 500 composite's +13.4% change. Currently, A carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Agilent (A) Q2 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, Agilent Technologies (A - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.27 per share, reflecting an increase of 4.1% compared to the same period last year. Revenues are forecasted to be $1.63 billion, representing a year-over-year increase of 3.3%.
The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Agilent metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenue by End Markets- Diagnostics and Clinical' at $247.93 million. The estimate suggests a change of +3.7% year over year.
Analysts predict that the 'Revenue by End Markets- Chemical and advanced materials' will reach $370.20 million. The estimate points to a change of +2.3% from the year-ago quarter.
The consensus among analysts is that 'Revenue by End Markets- Food' will reach $146.05 million. The estimate indicates a year-over-year change of +5.1%.
Analysts expect 'Revenue by End Markets- Academia and Government' to come in at $145.13 million. The estimate suggests a change of +4.4% year over year.
Analysts' assessment points toward 'Net Revenue- Life Sciences and Applied Markets Group' reaching $628.72 million. The estimate suggests a change of -16.6% year over year.
The consensus estimate for 'Net Revenue- Agilent Crosslab Group' stands at $697.53 million. The estimate indicates a year-over-year change of +73.5%.
Analysts forecast 'Revenue by End Markets- Pharmaceutical' to reach $572.63 million. The estimate indicates a change of +5.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue by End Markets- Environmental and Forensics' should come in at $159.54 million. The estimate points to a change of +5% from the year-ago quarter.
View all Key Company Metrics for Agilent here>>>
Over the past month, shares of Agilent have returned +3.7% versus the Zacks S&P 500 composite's +13.4% change. Currently, A carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>